Bio-Rad Laboratories (NYSE:BIO) EVP Courtney Enloe Sells 902 Shares of Company Stock

Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) EVP Courtney Enloe sold 902 shares of the firm’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $386.17, for a total value of $348,325.34. Following the sale, the executive vice president directly owned 750 shares in the company, valued at approximately $289,627.50. This trade represents a 54.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Bio-Rad Laboratories Stock Down 4.0%

Shares of BIO stock opened at $370.41 on Friday. Bio-Rad Laboratories, Inc. has a twelve month low of $236.73 and a twelve month high of $396.23. The stock has a market cap of $9.90 billion, a P/E ratio of 9.76 and a beta of 1.06. The stock has a 50 day moving average of $373.46 and a 200 day moving average of $317.11. The company has a current ratio of 3.18, a quick ratio of 2.37 and a debt-to-equity ratio of 0.11.

Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical research company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.23 by $0.42. The business had revenue of $656.40 million for the quarter, compared to analyst estimates of $649.94 million. Bio-Rad Laboratories had a return on equity of 3.58% and a net margin of 39.45%. The business’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.26 EPS. As a group, sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 9.71 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its position in shares of Bio-Rad Laboratories by 1.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,089,323 shares of the medical research company’s stock worth $303,637,000 after purchasing an additional 12,251 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Bio-Rad Laboratories by 57.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 233,227 shares of the medical research company’s stock worth $68,478,000 after buying an additional 85,393 shares during the last quarter. Hosking Partners LLP boosted its holdings in Bio-Rad Laboratories by 1.1% in the 3rd quarter. Hosking Partners LLP now owns 95,472 shares of the medical research company’s stock worth $36,061,000 after buying an additional 1,042 shares during the last quarter. Hound Partners LLC boosted its holdings in Bio-Rad Laboratories by 125.9% in the 1st quarter. Hound Partners LLC now owns 97,724 shares of the medical research company’s stock worth $27,241,000 after buying an additional 54,456 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new stake in Bio-Rad Laboratories during the 2nd quarter worth approximately $17,690,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BIO shares. Wells Fargo & Company boosted their target price on shares of Bio-Rad Laboratories from $310.00 to $330.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. Zacks Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Weiss Ratings raised shares of Bio-Rad Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday. Citigroup lifted their price objective on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Finally, Royal Bank Of Canada upped their price objective on shares of Bio-Rad Laboratories from $390.00 to $440.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. One equities research analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $366.67.

Read Our Latest Report on BIO

Bio-Rad Laboratories Company Profile

(Get Free Report)

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products used in life science research and clinical diagnostics. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, and serves customers around the world. Through its Life Science segment, Bio-Rad supplies instruments, reagents, and software for areas including cell biology, genomics, protein analysis, and drug discovery. Its products support research at academic institutions, biotechnology and pharmaceutical companies, and other laboratories.

See Also

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.